-The Telegraph New Delhi: A health consortium today questioned a decision by Delhi High Court earlier this week to quash the Centre's ban on 344 cocktails of two or more medicines and urged doctors across the country to stop prescribing them. The Jan Swasthya Abhiyan (JSA), the Indian section of the global People's Health Movement, said it was shocked at the judgment because there was "no scientific rationale" for the continued use...

-The Hindu The National Medical Commission Bill’s proposal to permit ‘for profit’ colleges will undermine the aim of creating a cadre of medical professionals able and willing to work in small towns and villages The many reports commissioned by the Government of India on the state of medical care invariably highlight one fact: a large number of Indians do not have access to proper and adequate medical care. India currently faces a “double...

-PTI Assuming 80% availability of doctors, it is estimated around 7.67 lakh (allopathic) doctors may be actually available for service There is one doctor for every 893 patients in the country if allopathic doctors and those practising Ayurveda, Unani and Homeopathy streams are considered together, Lok Sabha was informed today. In a written reply, Minister of State for Health Faggan Singh Kulaste said there as 9.59 lakh registered allopathic doctors in the country...

-The Hindu Medicines remain overpriced and unaffordable in India. In a country mired in poverty, medical debt remains the second biggest factor for keeping millions in poverty. The international pharmaceutical industry has found its cash cow in India’s beleaguered consumers. With a minimum wage of Rs.250/day for a government worker, a basic wage worker afflicted with a chronic disease like multi-drug-resistant tuberculosis faces penury. His treatment, with drug combinations, which works out...

-The Times of India NEW DELHI: In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial new direct-acting antiviral drugs treating the disease. The waiver for sofosbuvir and ledipasvir co-formulation and for daclatasvir is expected to bring the generic version of these drugs, which cost a fraction...